Amneal Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | $2.59B | $298.4M | $26.0M |
| FY2023 | $2.39B | $19.8M | $91.5M |
| FY2024 | $2.16B | $-109.3M | $110.6M |
| FY2025 | $2.57B | $-70.8M | $282.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | $2.59B | $298.4M | $26.0M |
| FY2023 | $2.39B | $19.8M | $91.5M |
| FY2024 | $2.16B | $-109.3M | $110.6M |
| FY2025 | $2.57B | $-70.8M | $282.0M |